高级检索

乳腺癌骨转移骨相关事件对患者生存期的影响

Effects of skeletal-related events on survival in breast cancer patients with bone metastases

  • 摘要: 目的:探讨乳腺癌骨转移骨相关事件(skeletal-related events,SREs)的发生及SREs对患者生存期的影响。方法:选择复旦大学附属中山医院和上海市黄浦区中心医院收治的乳腺癌骨转移患者。将患者分为不伴SREs组和伴SREs组,比较两组患者的基本临床特征、骨转移特征,分析SREs的特点及SREs对乳腺癌骨转移患者的骨转移生存期(BS)和总生存期(OS)的影响。 结果:乳腺癌骨转移患者共104例,不伴SREs组和伴SREs组分别为46例、58例。两组间年龄、手术方式、肿瘤组织类型、美国癌症联合会(American Joint Committee on Cancer, AJCC)分期、骨转移间歇期、骨转移部位等差异无统计学意义,骨转移数目差异有统计学意义(P=0.006)。骨相关事件间歇期0~48个月,中位时间为5.5(1.0,20.5)个月。SREs以骨痛最多,占70.6%。不伴SREs组和伴SREs组间BS(HR=1.043,95%CI 0.608~1.790,P=0.878)和OS(HR=0.927,95%CI 0.543~1.581,P=0.781)差异无统计学意义。结论:SREs不增加乳腺癌骨转移患者的死亡风险。

     

    Abstract: Objective:To explore the effects of skeletal-related events (SREs) on survival in breast cancer patients with bone metastases. Methods:The breast cancer patients with bone metastases in Zhongshan Hospital affiliated to Fudan University and Huangpu District Central Hospital in Shanghai were collected, and divided into SREs group and non-SREs group. The basic clinical characteristics and bone metastases characteristics were compared between two groups. The characteristics of SREs were observed and the effects of SREs on bone survivals (BS) and overall survivals (OS) were analyzed. Results:Totally, 104 cases of breast cancer with bone metastases including 46 cases without SREs (non-SREs group) and 58 cases with SREs (SREs group) were enrolled. The age, type of surgery, histological type, stage of American Joint Committee on Cancer (AJCC), bone metastasis-free interval (BMFI), bone metastases sites were not significantly different between the two groups, while the number of bone metastases was significantly different (P=0.006). The time of skeletal-related events-free interval (SREFI) was from 0 to 48 months, with median time of 5.5(1.0,20.5) months. The most common SREs was bone pain (70.6%). No significant differences in BS (HR=1.043, 95%CI 0.608-1.790, P=0.878) and OS (HR=0.927, 95%CI 0.543-1.581, P=0.781) were noted between two groups. Conclusions:SREs do not increase the risk of death in breast cancer patients with bone metastases.

     

/

返回文章
返回